Cognition Therapeutics Improved Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s

  CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -

- Consistent Positive Changes Across Cognitive and Functional Measures -
- Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate -
- Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration -
- Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings

The majority of adverse events were mild or moderate in severity. The most commonly reported treatment-emergent adverse events were infections and infestations (urinary tract infection), injury, poisoning and procedural complications (falls and skin lacerations), gastrointestinal disorders and nervous system disorders (headache).

AAIC Presentation details
Title:	Clinical Efficacy Results from COG0201: a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease
Authors:	Vijverberg EGB, Catalano S, Hamby ME, Grundman M, Iaci J, Devins T, Caggiano AO
Date/Time:	July 29, 2024: 8:30 a.m. - 4:15 p.m. Eastern Time
Location:	Pennsylvania Convention Center, Philadelphia, PA

This and Cognition’s other AAIC posters will be available on the Company’s Publication webpage in accordance with the conference’s embargo policy.

Webcast Information 
Company management will be joined by an investigator in the SHINE study, Everard (Jort) Vijverberg, MD, PhD of the Alzheimer Center Amsterdam and Neuroscience Amsterdam, who will present an overview of the results. In addition, Martin J. Sadowski, MD, PhD, DSci of New York University School of Medicine will participate as an Alzheimer’s industry expert. A live question and answer session will follow formal presentations. Interested parties may register from the event listing on the Cognition Therapeutics Investor Relations webpage under News & Events or directly by visiting https://lifescievents.com/event/cognition/.

https://www.globenewswire.com/news-release/2024/07/29/2920165/0/en/Cognition-Therapeutics-Proof-of-Concept-Phase-2-SHINE-Trial-Demonstrates-Consistent-Improvement-in-Cognitive-Outcomes-with-Once-Daily-Oral-CT1812-in-Mild-to-Moderate-Alzheimer-s-Pa.html